Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic obstructive pulmonary disease (COPD)
Biotech
Connect drug reduces COPD attacks 85%, misses a secondary goal
Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce respiratory attacks.
James Waldron
Sep 30, 2026 8:54am
Connect not dismayed by Dupixent rival's ph. 2 asthma failure
Sep 15, 2026 9:55am
AZ's 'science success story' with tozorakimab plays out in full
Sep 8, 2026 10:50am
Sanofi-backed Expedition lands $115M for ph. 2 COPD trial
Aug 5, 2026 8:00am
AstraZeneca pens $2.1B deal for challenger to Merck’s Ohtuvayre
Jul 8, 2026 5:00am
AstraZeneca’s faith in IL-33 blocker pays off with new ph. 3 win
Apr 20, 2026 7:22am
